









Markets
/
Stocks
/
nasdaq-adtx
/

Aditxt Inc

ADTX

5.880USD

+0.680+13.08%

Market hours （ET）Quotes delayed by 15 min

18.68MMarket Cap

LossP/E TTM



Aditxt Inc

5.880

+0.680+13.08%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Aditxt Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,Despite a strong stock market performance, the company shows strong fundamentals and technicals, which don't support the current strong trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Aditxt Inc's Score

Industry at a Glance

Industry Ranking

248 / 407

Overall Ranking

538 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Aditxt Inc Highlights

StrengthsRisks

Aditxt, Inc. is a biotech company focused on discovering, developing, and deploying health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.

Growing

The company is in a growing phase, with the latest annual income totaling USD 133.99K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 133.99K.

Fairly Valued

The company’s latest PE is 0.00, at a medium 3-year percentile range.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 5.06, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 1.00K, representing a year-over-year decrease of 97.73%, while its net profit experienced a year-over-year decrease of 3.88%.

Score

Industry at a Glance

Previous score

5.06

Change



Financials

3.92

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.75

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.95

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Aditxt Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 6.43, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is 0.00, which is +Inf% below the recent high of 0.01 and +Inf% above the recent low of -0.90.

Score

Industry at a Glance

Previous score

6.43

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 248/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 1.01, which is lower than the Biotechnology & Medical Research industry's average of 6.41. Sideways: Currently, the stock price is trading between the resistance level at 8.21 and the support level at 1.12, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.01

Change

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MACD(12,26,9)

1.108

Buy

RSI(14)

77.824

Buy

STOCH(KDJ)(9,3,3)

60.195

Buy

ATR(14)

0.657

High Vlolatility

CCI(14)

211.835

Overbought

Williams %R

27.279

Buy

TRIX(12,20)

4.401

Buy

StochRSI(14)

80.437

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

2.390

Buy

MA10

1.309

Buy

MA20

0.898

Buy

MA50

0.921

Buy

MA100

1.057

Buy

MA200

5.553

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-04

Score

Industry at a Glance

Previous score

0.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

No Data

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 1.81, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.23. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.